Therefore, the combination of anti-VEGF/VEGFR and immunotherapy can enhance tumor immunity by multiple ways, such as relieving the inhibition of antigen presentation and inhibiting the recruitment of immunosuppressive cells. Here, KDR is linked to neoplasm.